Press Releases

AMSTERDAM--(BUSINESS WIRE)-- AM Best has maintained the under review with negative implications status for the Financial Strength Rating of B++ (Good) and the Long-Term Issuer Credit Rating of “bbb+” (Good) of Cowen Reinsurance S.A. (Cowen Re) (Luxembourg).

The Credit Ratings (ratings) reflect Cowen Re’s balance sheet strength, which AM Best assesses as very strong, as well as its adequate operating performance, limited business profile and appropriate... (continue reading...)

Silver Spring, Md., June 07, 2024 (GLOBE NEWSWIRE) -- Today, Urban One, the largest Black owned media company in the country, received an astounding twenty-one wins are this year’s 2024 Telly Awards, which represent the best in video and television across all screens. Led by One Solution, Urban One's award-winning integrated marketing, strategic partnerships and branded content studio division and flagship cable network TV One. 

"We are, once again, beyond... (continue reading...)

- After 5 years of treatment, 91% of children were alive — without treatment, children with Type 1 SMA would not be expected to live past 2 years of age -

- 96% of Evrysdi-treated children could swallow, 80% could feed without a feeding tube and 59% could sit without support for at least 30 seconds -

- Evrysdi is now approved in more than 100 countries with over 15,000 patients treated globally -

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a... (continue reading...)

Aspermont, a leading media services provider, in partnership with Rule Investment Media, is organizing the Mining News Select Perth, coming up June 17-18, 2024 in Pan Pacific Perth. The event focuses on providing resources, connections, and higher ROI, to global resource companies in the minerals and gold sector.

Aspermont caters to the global resource industries. With over 20+ years of creating a commercial model for B2B media, Aspermont offers high-value content... (continue reading...)

• After five years of treatment, 91% of children were alive — without treatment, children with Type 1 SMA would not be expected to live past two years of age
• 96% of Evrysdi-treated children could swallow, 80% could feed without a feeding tube and 59% could sit without support for at least 30 seconds
• Evrysdi is now approved in more than 100 countries with over 15,000 patients treated globally

Basel, 07 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new... (continue reading...)